BR0314751A - Partìculas adequadas para suprimento a partir de um dispositivo de suprimento, receptáculo de dosagem para um dispositivo de suprimento, dispositivo de suprimento mediado por partìcula, processo para a preparação de partìculas adequadas para suprimento a partir de um dispositivo de suprimento, e, métodos de imunização por ácido nucleico e de terapia genética - Google Patents

Partìculas adequadas para suprimento a partir de um dispositivo de suprimento, receptáculo de dosagem para um dispositivo de suprimento, dispositivo de suprimento mediado por partìcula, processo para a preparação de partìculas adequadas para suprimento a partir de um dispositivo de suprimento, e, métodos de imunização por ácido nucleico e de terapia genética

Info

Publication number
BR0314751A
BR0314751A BR0314751-7A BR0314751A BR0314751A BR 0314751 A BR0314751 A BR 0314751A BR 0314751 A BR0314751 A BR 0314751A BR 0314751 A BR0314751 A BR 0314751A
Authority
BR
Brazil
Prior art keywords
supply device
supply
nucleic acid
particles suitable
particles
Prior art date
Application number
BR0314751-7A
Other languages
English (en)
Inventor
Chris Robert Lively
Robert Delong
Original Assignee
Powderject Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32043345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314751(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Powderject Res Ltd filed Critical Powderject Res Ltd
Publication of BR0314751A publication Critical patent/BR0314751A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Ceramic Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PARTìCULAS ADEQUADAS PARA SUPRIMENTO A PARTIR DE UM DISPOSITIVO DE SUPRIMENTO, RECEPTáCULO DE DOSAGEM PARA UM DISPOSITIVO DE SUPRIMENTO, DISPOSITIVO DE SUPRIMENTO MEDIADO POR PARTìCULA, PROCESSO PARA A PREPARAçãO DE PARTìCULAS ADEQUADAS PARA SUPRIMENTO A PARTIR DE UM DISPOSITIVO DE SUPRIMENTO E MéTODOS DE IMUNIZAçãO POR áCIDO NUCLEICO E DE TERAPIA GENéTICA CAMPO TéCNICO". São providas partículas que são adequadas para suprimento a partir de um dispositivo de suprimento mediado por partículas. As partículas são obtidas precipitando-se um ácido nucleico em particulas portadoras de metal inerte, na presença de um agente condensador de ácido nucleico e um agente quelante de íon metálico. Também são descritos processos para preparar as partículas e métodos terapêuticos utilizando as partículas, incluindo métodos de imunização por ácido nucleico e terapia genética.
BR0314751-7A 2002-09-27 2003-09-29 Partìculas adequadas para suprimento a partir de um dispositivo de suprimento, receptáculo de dosagem para um dispositivo de suprimento, dispositivo de suprimento mediado por partìcula, processo para a preparação de partìculas adequadas para suprimento a partir de um dispositivo de suprimento, e, métodos de imunização por ácido nucleico e de terapia genética BR0314751A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41409702P 2002-09-27 2002-09-27
PCT/GB2003/004202 WO2004028560A1 (en) 2002-09-27 2003-09-29 Nucleic acid coated particles

Publications (1)

Publication Number Publication Date
BR0314751A true BR0314751A (pt) 2005-07-26

Family

ID=32043345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314751-7A BR0314751A (pt) 2002-09-27 2003-09-29 Partìculas adequadas para suprimento a partir de um dispositivo de suprimento, receptáculo de dosagem para um dispositivo de suprimento, dispositivo de suprimento mediado por partìcula, processo para a preparação de partìculas adequadas para suprimento a partir de um dispositivo de suprimento, e, métodos de imunização por ácido nucleico e de terapia genética

Country Status (16)

Country Link
US (1) US8349364B2 (pt)
EP (1) EP1545593A1 (pt)
JP (1) JP4791730B2 (pt)
KR (1) KR101152561B1 (pt)
CN (1) CN100542605C (pt)
AU (1) AU2003269213B2 (pt)
BR (1) BR0314751A (pt)
CA (1) CA2500215C (pt)
EA (1) EA010881B1 (pt)
GB (1) GB2410497B (pt)
IL (1) IL167635A (pt)
MX (1) MXPA05003222A (pt)
NZ (1) NZ539107A (pt)
PL (1) PL212483B1 (pt)
WO (1) WO2004028560A1 (pt)
ZA (1) ZA200503380B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004068110A2 (en) 2003-01-24 2004-08-12 University Of Utah Methods of predicting mortality risk by determining telomere length
JP4793956B2 (ja) * 2005-12-29 2011-10-12 ニチコン株式会社 アルミニウム電解コンデンサの駆動用電解液、およびこれを用いたアルミニウム電解コンデンサ
US9689028B2 (en) 2008-12-22 2017-06-27 University Of Utah Foundation Monochrome multiplex quantitative PCR
GB0918679D0 (en) 2009-10-23 2009-12-09 Iqur Ltd Influenza vaccine
GB0918782D0 (en) 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
EP3004173B1 (en) 2013-06-06 2018-05-30 iQur Limited Single domain antibody display
CN103736090B (zh) * 2014-01-27 2016-03-02 中国医学科学院医学生物学研究所 甲磺酸去铁胺佐剂及含甲磺酸去铁胺佐剂的疫苗
EP3164156A1 (en) * 2014-07-04 2017-05-10 BioNTech AG Stabilised formulations of rna
US9944978B2 (en) 2014-12-30 2018-04-17 Telomere Diagnostics, Inc. Multiplex quantitative PCR
EP3761962A4 (en) * 2018-03-07 2021-12-15 ReForm Biologics, Inc. EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS
TWI788643B (zh) 2019-09-29 2023-01-01 美洛生物科技股份有限公司 新穎三甲基甘胺醯甘油組成物及其發展抗癌症藥物及ｒｎａ疫苗上的用途
WO2021085564A1 (ja) * 2019-10-30 2021-05-06 株式会社ダイセル 遺伝子銃
WO2024243873A1 (zh) * 2023-05-31 2024-12-05 深圳华大智造科技股份有限公司 一种调整核酸纳米球体积的方法及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5120657A (en) * 1986-12-05 1992-06-09 Agracetus, Inc. Apparatus for genetic transformation
KR900007952B1 (ko) * 1988-11-18 1990-10-23 주식회사 녹십자 신규의 한탄바이러스 rok84/105 균주 및 이를 이용한 한탄바이러스 백신의 제조방법
US5204253A (en) * 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5149655A (en) * 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
CA2051092C (en) * 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
ATE207126T1 (de) * 1991-05-15 2001-11-15 Monsanto Technology Llc Verfahren zur schöpfung einer transformierten reispflanze
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
GB2284208A (en) * 1993-11-25 1995-05-31 Pna Diagnostics As Nucleic acid analogues with a chelating functionality for metal ions
CA2158733C (en) * 1994-01-21 2007-01-16 Dennis E. Mccabe Gas driven gene delivery instrument
GB9416663D0 (en) 1994-08-17 1994-10-12 Oxford Bioscience Limited Particle delivery
CA2199417C (en) 1994-10-24 2008-07-08 Brian John Bellhouse Particle delivery
GB9426379D0 (en) 1994-12-23 1995-03-01 Oxford Biosciences Ltd Particle delivery
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
EP0906110B1 (en) 1996-04-26 2004-12-22 Merck & Co., Inc. Dna vaccine formulations
IN184589B (pt) * 1996-10-16 2000-09-09 Alza Corp
AU4973199A (en) 1998-07-09 2000-02-01 Merck & Co., Inc. Polynucleotide vaccine formulations
CA2349505A1 (en) * 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization
ATE342089T1 (de) * 1999-06-02 2006-11-15 Boston Scient Ltd Arzneimittelabgabevorrichtungen
WO2001083528A2 (en) 2000-05-01 2001-11-08 Powderject Vaccines, Inc. Nucleic acid immunization
US20040142475A1 (en) * 2000-06-02 2004-07-22 Barman Shikha P. Delivery systems for bioactive agents

Also Published As

Publication number Publication date
US20060153804A1 (en) 2006-07-13
EA010881B1 (ru) 2008-12-30
HK1073797A1 (en) 2005-10-21
KR101152561B1 (ko) 2012-06-01
CA2500215C (en) 2012-02-28
EP1545593A1 (en) 2005-06-29
CN100542605C (zh) 2009-09-23
AU2003269213B2 (en) 2008-11-13
PL212483B1 (pl) 2012-10-31
IL167635A (en) 2011-07-31
MXPA05003222A (es) 2005-07-26
ZA200503380B (en) 2007-11-28
CN1694721A (zh) 2005-11-09
GB2410497A (en) 2005-08-03
PL375782A1 (en) 2005-12-12
GB0508549D0 (en) 2005-06-01
EA200500546A1 (ru) 2005-10-27
US8349364B2 (en) 2013-01-08
JP4791730B2 (ja) 2011-10-12
WO2004028560A1 (en) 2004-04-08
AU2003269213A1 (en) 2004-04-19
KR20050070008A (ko) 2005-07-05
NZ539107A (en) 2008-11-28
CA2500215A1 (en) 2004-04-08
JP2006503063A (ja) 2006-01-26
GB2410497B (en) 2006-11-22

Similar Documents

Publication Publication Date Title
BR0314751A (pt) Partìculas adequadas para suprimento a partir de um dispositivo de suprimento, receptáculo de dosagem para um dispositivo de suprimento, dispositivo de suprimento mediado por partìcula, processo para a preparação de partìculas adequadas para suprimento a partir de um dispositivo de suprimento, e, métodos de imunização por ácido nucleico e de terapia genética
Balke-Want et al. Non-viral chimeric antigen receptor (CAR) T cells going viral
Ishaqat et al. Polymers strive for accuracy: from sequence-defined polymers to mRNA vaccines against COVID-19 and polymers in nucleic acid therapeutics
Kamali et al. CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells
WO2005030118A3 (en) Targeted release of nitric oxide in the cns circulation for modulating the bbb and treating disorders
DE69733881D1 (en) Plastidtransformation in arabidopsis thaliana
WO2001016312A3 (en) Nucleic acid based modulators of gene expression
AR024008A1 (es) Uso de microesferas biodegradables que liberan un agente anticancerigeno, para el tratamiento de glioblastoma, proceso para la preparacion de estasmicroesferas y suspension que contiene a las mismas
IL156780A0 (en) Modular transfection systems
WO2019147743A1 (en) Structure-guided chemical modification of guide rna and its applications
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
GB2377447B (en) Isolation of dna molecules
WO2005072893A8 (en) Functionalized colloidal metal compositions and methods
Wang et al. DNA protection against damages induced by low-energy electrons: Absolute cross sections for arginine–DNA complexes
AU6120600A (en) Herpes simplex virus expressing foreign genes and method for treating cancers therewith
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
WO2007126787A3 (en) Reagents and methods for cancer treatment and prevention
WO2004013313A3 (en) Antisense nucleic acids
GB9816583D0 (en) Nucleic acid carrier
Schneider-Bernloehr et al. Partial resolution of DL-adenosine by template synthesis
IL131436A0 (en) Compositions for treatment of disorders involving programmed cell death
GB0216081D0 (en) Methods of making biological materials and uses thereof
WO2001030989A3 (en) Method for creating divergent populations of nucleic acid molecules and proteins
DE69938501D1 (de) Verwendung von prohibitin-rns in krebsbehandlung
DE60030850D1 (de) Verfahren zur behandlung von tumoren mittels antiangiogener substanzen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL